If you're an income-seeking investor, a buoyant stock market near its all-time high is actually a problem. At recent prices, the average stock in the benchmark S&P 500 index offers an itty-bitty 1.2% dividend yield.A low average dividend yield suggests the market is overbought, but that doesn't mean there aren't any hidden gems out there. UnitedHealth Group (UNH) and Prologis (PLD) have been flying under the radar even though they both offer yields that are more than double the benchmark average.UnitedHealt ...

Centene Corporation (NYSE: CNC ) offers a variety of healthcare insurance products, including Medicare, Medicaid, and more. A few days ago, shares of this company plunged after the company withdrew guidance for 2025, with much of this being driven byLong-time stock market investor focused on strategic buying opportunities with dividend and value stocks. This investment strategy has resulted in a near 5 star rating on Tipranks.com and over 9,000 followers on Seeking Alpha. Follow me on Twitter for my latest ...

Manipal Health has acquired a majority stake in Sahyadri Hospitals for about $700 million, adding to a flurry of health care deals in India and challenging the dominance of Apollo Hospitals https://t.co/VTKF8eWZpc ...

1. 申报重点领域 北京市重点实验室的布局将紧密围绕北京国际科技创新中心建设，重点支持以下领域： 新一代信息技术（如人工智能、大数据、5G/6G通信等）； 智能制造与装备（如工业互联网、智能机器人、高端装备制造等）； 新材料（如高性能材料、纳米材料、新能源材料等）； 新能源（如清洁能源、储能技术、碳中和相关技术等）。 特别提示 微信机制调整，点击顶部"仪器信息网" → 右上方"…" → 设为 ★ 星标，否则很可能无法看到我们 的推送。 7月9日， 北京市科学技术委员会、中关村科技园区管理委员会联合发布了《2025年北京市重 点实验室申报指南》（京科机发〔2025〕135号）， 正式启动本年度北京市重点实验室申报 工作 。2025年北京市重点实验室申报工作紧密围绕北京国际科技创新中心建设的重点任务， 聚焦本市重点产业方向和前沿科技领域。申报领域 涵盖新一代信息技术、 医药健康、智能制 造与装备、新材料、新能源、农业科技 、智慧城市等关键领域。 （ 文 末 附 申 报 案 例 ） 医药健康（如生物医药、医疗器械、精准医疗等）； 智能制造与装备作为核心方向之一，将重点关注工业自动化、智能检测、数字孪生、工业软件 等 ...

Core Viewpoint - Hims & Hers Health, Inc. is facing two securities class action lawsuits due to allegations of deceptive marketing practices and failure to disclose critical information, particularly related to its collaboration with Novo Nordisk and the weight loss drug Wegovy® [1][4][5] Group 1: Lawsuits and Allegations - Two class action lawsuits were filed against Hims & Hers Health, Inc. and certain executives, representing investors who acquired securities between April 29, 2025, and June 23, 2025 [1] - The lawsuits allege that Hims & Hers made false and misleading statements and engaged in deceptive promotion of knockoff versions of Wegovy®, which jeopardized patient safety and led to the termination of its collaboration with Novo Nordisk [4][5] - The lawsuits were prompted by Novo Nordisk's announcement on June 23, 2025, that it terminated its collaboration due to concerns over Hims & Hers' illegal practices and deceptive marketing [2][5] Group 2: Investor Impact and Actions - Following the termination of the collaboration, Hims & Hers shares experienced a significant decline of 30% [2] - Hagens Berman, a national shareholders rights firm, is investigating the claims and encourages affected investors to submit their losses [3][6] - The lead plaintiff deadline for the lawsuits is set for August 25, 2025 [3] Group 3: Whistleblower Information - Individuals with non-public information regarding Hims & Hers are encouraged to assist in the investigation or consider the SEC Whistleblower program, which offers rewards for original information leading to successful recoveries [7]

SAN DIEGO, July 9, 2025 /PRNewswire/ -- Robbins Geller Rudman & Dowd LLP announces that the Centene class action lawsuit seeks to represent purchasers or acquirers of Centene Corporation (NYSE: CNC) securities between December 12, 2024 and June 30, 2025, inclusive (the "Class Period"). Captioned Lunstrum v. Centene Corporation, No. 25-cv-05659 (S.D.N.Y.), the Centene class action lawsuit charges Centene and certain of Centene's top executives with violations of the Securities Exchange Act of 1934.If you suf ...

Core Viewpoint - A class action lawsuit has been filed against Centene Corporation, alleging that the company misled investors about its business prospects and financial outlook during the specified period [1][2]. Allegations - The complaint claims that Centene's management created a false impression of having reliable information regarding projected revenue and growth, while actual enrollment rates and morbidity were lower than expected [2]. - A preliminary analysis indicated that over two-thirds of Centene's marketplace share showed disappointing enrollment figures and increased morbidity, contradicting the company's optimistic reports [2]. Financial Impact - On July 1, 2025, Centene withdrew its 2025 guidance, revealing that its overall market growth across 22 states was lower than anticipated, leading to a revised guidance of approximately $1.8 billion and an adjusted diluted EPS of $2.75 [3]. - Following this announcement, Centene's stock price plummeted from $56.65 per share to $44.78 per share on July 2, 2025, marking a decline of over 40% [3].

Core Viewpoint - The Department of Justice is investigating UnitedHealth for allegedly encouraging staff to make specific diagnoses that would lead to higher Medicare payments, particularly under the Medicare Advantage program [1][6]. Investigation Details - The investigation involves inquiries from the Justice Department, FBI, and Health and Human Services regarding patient testing, diagnostic procedures, and the process of sending nurses to patients' homes [2]. - Former employees reported that investigators asked about training related to making diagnoses and the methods used to contact patients for testing [4][8]. Company Response - UnitedHealth maintains that it supports the integrity of its Medicare Advantage business and welcomes regular reviews of its practices [3]. - The company criticized the Wall Street Journal for what it perceives as a biased narrative against Medicare Advantage, claiming reliance on incomplete data [3][4]. Diagnostic Practices - Former doctors indicated that the focus was on coding practices, specifically how diagnosis codes are submitted to Medicare for payments [5]. - Investigators inquired about bonuses for doctors reviewing potential diagnoses suggested by UnitedHealth [7]. Software and Tools - The investigation also looked into the "diagnosis cart" feature of UnitedHealth's software, which suggests potential medical conditions to nurses [11]. - UnitedHealth argues that its diagnostic practices are aimed at early disease detection and plans to implement independent third-party oversight for these practices [8]. Previous Investigations - A separate decade-long effort by the Justice Department to recover alleged Medicare overpayments from UnitedHealth was unsuccessful [10].

Core Viewpoint - UnitedHealth Group, Inc. is facing increased legal challenges as shareholders file multiple lawsuits related to a federal investigation into the company's Medicare billing practices, which were highlighted in a Wall Street Journal report [1][3]. Summary by Sections Legal Actions - Steve Silverman, a long-time shareholder, has filed a derivative lawsuit in federal court, claiming that UnitedHealth's leadership has harmed the company through questionable billing practices [2]. - The lawsuit accuses CEO Stephen Hemsley, former CEO Andrew Witty, and board members of engaging in practices that led to inflated reimbursements, significantly impacting the company's financial results and stock price [3][4]. - Other shareholders have also filed lawsuits, with one alleging that Hemsley and Witty profited from stock sales before the DOJ investigation became public [5][6]. Financial Impact - The lawsuits focus on the profitability of UnitedHealth's Medicare business, which has drawn negative attention and affected its stock price [6]. - Allegations include that the company repurchased $7.3 billion in stock at inflated prices while executives profited from share sales during the undisclosed DOJ investigation [9]. Company Challenges - UnitedHealth is currently navigating a series of challenges, including ongoing lawsuits, a DOJ investigation, regulatory changes, and leadership changes following the resignation of CEO Andrew Witty [7][10]. - The company's stock has seen a significant decline, falling over 40% year-to-date, with shares trading at $302.10 at the time of the report [11].

Core Insights - Medical Properties Trust (MPW) shares have increased by 14% over the past six months, outperforming the industry growth of 9.8% [1][9] - The company focuses on acquiring and developing net-leased healthcare facilities, including hospitals and urgent care facilities [1] Industry Trends - The senior citizens' population is projected to rise, leading to increased national healthcare expenditures, particularly from this demographic [2] - The healthcare sector is relatively insulated from macroeconomic challenges, providing stability amid market volatility [3] Company Operations - MPW leases facilities to healthcare operating companies with initial lease terms of at least 15 years, most including five-year renewal options [4] - Over 99% of leases have annual rent escalations tied to the Consumer Price Index [4] Financial Position - Strategic asset sales have provided MPW with capital for reinvestment; in Q1 2025, the company sold facilities for approximately $20 million, realizing a gain of $8.1 million [5] - As of May 7, 2025, MPW has approximately $1.3 billion in liquidity and no debt maturities due in the next twelve months, enhancing its financial flexibility [6] Future Outlook - Given the favorable demographic trends and strong financial position, the positive stock trend for MPW is expected to continue in the near term [7]